America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy‘.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
What challenges did Dr. Malkas and her team face during the development of the targeted chemotherapy drug AOH1996?
**Interview with Dr. Linda Malkas on the Development of a New Targeted Chemotherapy Drug**
**Editor:** Today, we have Dr. Linda Malkas from the City of Hope Hospital, a leading researcher in cancer therapies. Dr. Malkas, thank you for joining us.
**Dr. Malkas:** Thank you for having me. It’s a pleasure to discuss our exciting findings.
**Editor:** Let’s dive right in. Your team has developed a new pill called AOH1996. Can you explain how it works and what makes it different from traditional chemotherapy?
**Dr. Malkas:** Absolutely. AOH1996 is designed to target a specific protein variant known as PCNA, which is crucial for DNA replication in cancer cells. Unlike traditional chemotherapy, which often affects both healthy and cancerous cells, our approach selectively zeroes in on the mutated form of PCNA found in tumors. Think of it as a ‘blizzard’ that disrupts operations at an airline hub, specifically halting the flights that are only bringing in cancer cells, while leaving other processes intact.
**Editor:** That’s a fascinating analogy. Have there been any trials to test its effectiveness?
**Dr. Malkas:** Yes, indeed. In our recent study published in *Cell Chemical Biology*, we tested AOH1996 on more than 70 cancer cell lines, including those from breast, prostate, brain, and lung cancers. The results showed that this drug effectively kills cancer cells by disrupting their reproductive cycles without affecting normal cells as much.
**Editor:** That sounds promising. Can you tell us about the next steps in this research?
**Dr. Malkas:** The next crucial step is to advance our findings into clinical trials involving human subjects. We are optimistic about the potential of AOH1996 to improve patient outcomes with fewer side effects compared to conventional treatments.
**Editor:** I understand that you’ve been developing this drug over the past two decades. What challenges did you face during this journey?
**Dr. Malkas:** Developing targeted therapies is complex. One major challenge was identifying the unique mutations in PCNA that are present in cancerous cells. However, our persistence paid off by allowing us to create a solution that is more effective and targeted.
**Editor:** Dr. Malkas, thank you for sharing your insights! We look forward to seeing the results of the clinical trials.
**Dr. Malkas:** Thank you! I appreciate the opportunity to discuss our work, and I hope it brings hope to many battling cancer.
**Editor:** That wraps up our interview. Stay tuned for more updates on AOH1996 and other advancements in cancer treatments.